患者用移动应用报告药物不良反应的随机对照试验方案:Vigip-SEP研究
Vigip-SEP研究是一项多中心、开放、整群随机对照试验,旨在验证移动应用My eReport France®能否提高复发缓解型多发性硬化(RR-MS)患者对疾病修正药物(DMD)不良反应(ADR)的报告率。试验计划纳入24个中心共180例起始或转换一线DMD的RR-MS患者,主要评估指标为每患者每中心的平均ADR报告数,假设应用可使患者报告增加10倍。
要点
- 移动应用可能提升RR-MS患者对DMD不良反应的主动报告率。
- 主要终点为每患者每中心的平均ADR报告数,假设提升10倍。
- 试验采用整群随机设计,覆盖学术中心、综合医院和私人执业神经科医生。
核心结论
- 该研究旨在验证使用移动应用报告ADR能否增加RR-MS患者对DMD不良反应的报告。
研究设计与样本
- 多中心、开放、整群随机对照试验,使用My eReport France®应用按E2B格式向法国主管部门报告ADR。
- 纳入起始或转换一线DMD的RR-MS患者,计划24个中心(每臂12个:6个MS学术专家中心、3个综合医院、3个私人执业神经科医生),预期入组180例患者。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要评估指标为每患者每中心的平均ADR报告数。
- 假设应用可使患者报告增加10倍,计算样本量时采用α风险5%、把握度90%、标准差4%。
临床怎么用
- 在真实临床环境中,应鼓励教导患者使用移动应用等工具报告ADR,并对此类工具进行严格测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The reporting of adverse drug reactions (ADR) by patients represents an interesting challenge in the field of pharmacovigilance, but the reporting system is not adequately implemented in France. In 2015, only 20 MS patients in France reported ADR due to first-line disease-modifying drugs (DMD), while more than 3000 patients were initiated on DMD. The aim of this study is to validate a proof-of-concept as to whether the use of a mobile application (App) increases ADR reporting among patients with relapsing-remitting multiple sclerosis (RR-MS) receiving DMD. METHODS/DESIGN: We designed a multi-centric, open cluster-randomized controlled trial, called the Vigip-SEP study (NCT03029897), using the App My eReport France® to report ADR to the appropriate authorities in E2B language, in accordance with European regulations. RR-MS patients who were initiated on, or switched, first-line DMD will be included. In the experimental arm, a neurologist will introduce the patient to the App to report ADR to the appropriate French authorities. In the control arm, the patient will be informed of the existence of the App but will not be introduced to its use and will then report ADR according to the usual reporting procedures. Primary assessment criteria are defined as the average number of ADR per patient and per center. We assume that the App will increase patient reporting by 10-fold. Therefore, we will require 24 centers (12 per arm: 6 MS academic expert centers, 3 general hospitals, 3 private practice neurologists), allowing for an expected enrollment of 180 patients (alpha risk 5%, power 90% and standard deviation 4%). DISCUSSION: Increasing patient reporting of ADR in a real-life setting is extremely important for therapeutic management of RR-MS, particularly for monitoring newly approved DMD to gain better knowledge of their safety profiles. To increase patient involvement, teaching patients to use tools, such as mobile applications, should be encouraged, and these tools should be tested rigorously. TRIAL REGISTRATION: ClinicalTrials.gov , ID: NCT03029897 . Registered on 20 January 2017.
引用
- Defer G, Le Caignec F, Fedrizzi S, et al. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29523169. doi:10.1186/s13063-018-2560-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。